Presumptive Urine Drug Screens: Why Confirmation Matters

This material has not been verified by a trained forensic toxicologist. Read the full Content Disclaimer. A rapid urine drug screen can be useful. It can also be misunderstood. The most important question is often not whether the screening cup or immunoassay displayed a positive result, but what the test was designed to detect and whether an independent confirmatory method was performed.

A screen and a confirmation are different tests

Many initial urine drug screens are immunoassays. They use antibodies to recognize a drug, metabolite, or related molecular structure. They are fast and relatively inexpensive, which makes them useful for triage and high-volume testing.

That speed comes with a limitation: an antibody may respond to more than one compound. The response may also vary by manufacturer, assay generation, target drug class, and cutoff. For this reason, a positive immunoassay is generally described as presumptive until it is confirmed by a more specific analytical technique.

Confirmation commonly uses gas or liquid chromatography coupled with mass spectrometry. These methods separate compounds and identify them using chemical characteristics that are more specific than an antibody response.

What can produce an unexpected positive result?

An unexpected result does not have only one possible explanation. The review by Reisfield, Goldberger, and Bertholf describes a broader set of potentially misleading results. Relevant possibilities include:

cross-reactivity from a prescription or over-the-counter medication;
metabolism of one drug into another reportable compound;
exposure to a legitimate product containing a related substance;
an analyte present near the test cutoff;
specimen, labeling, or reporting error; and
a true exposure that the person did not disclose or recognize.

The possibility of interference is not proof of interference. A case-specific opinion requires the exact test platform, the package insert or validated cross-reactivity data, the medication and exposure history, and the confirmatory result.

Why amphetamine-class screens require special care

Amphetamine immunoassays are a familiar example because structurally related medications and compounds may produce a response in some assays. Saitman, Park, and Fitzgerald reviewed published false-positive interferences and emphasized the presumptive nature of immunoassay positives.

The correct next step is not to choose a medication from a generic internet list. It is to identify the assay and then determine whether that compound or its metabolites have documented cross-reactivity at a concentration that could plausibly have been present in the specimen.

Ayala-Lopez, Colby, and Hughey used 120,670 point-of-care screening and confirmation results to look for medication-related interference. Their analysis identified 446 presumptive-positive screens followed by negative confirmation. The researchers then tested six selected assay-medication pairs by adding compounds to drug-free urine. Labetalol produced a presumptive MDMA response at the tested concentration, while ranitidine affected selected methamphetamine, opiate, and propoxyphene channels at different concentrations.

The study is important for its method as much as its individual findings. An association in an electronic health record does not prove cross-reactivity, and a spiking result on one device does not establish what happened in another specimen tested on another assay.

Caricasole and colleagues reported an adult patient receiving therapeutic aripiprazole who produced presumptive amphetamine results while specific testing was negative. That case is a useful warning, but it remains one case. It does not prove that aripiprazole caused an unexpected result in every patient or on every amphetamine immunoassay.

Yee and Wu reported three pregnant patients receiving labetalol who had unexpected presumptive amphetamine results. The report proposed interference from a labetalol metabolite. That evidence is important but narrow: it is a three-patient case series, not proof that labetalol affects every assay or specimen type. A later laboratory study by Bithi and colleagues tested labetalol directly in urine, plasma, meconium, and umbilical-cord tissue. Labetalol did not produce false-positive results in the urine assays they tested, although it did affect a meconium immunoassay. Read together, the studies reinforce the same rule: medication-interference claims must identify the exact assay and specimen matrix.

Reidy, Walls, and Steele tested four amphetamine and methamphetamine ELISA kits using fortified urine and forensic case specimens. Two amphetamine kits responded to bupropion metabolites under the study conditions. Three case specimens screened positive with one amphetamine kit, did not confirm amphetamines by GC-MS, and contained bupropion and metabolites. That finding supports targeted investigation of bupropion when the exact assay is susceptible; it does not prove bupropion interference on every platform.

Vorce and colleagues investigated 134 Department of Defense specimens that screened positive for amphetamines but did not confirm by GC-MS. DMAA was detected by LC-MS/MS in 92.3% of those specimens at concentrations capable of producing responses on the two immunoassay kits studied. The paper explains a specific historical cluster. It does not mean DMAA explains every unconfirmed amphetamine screen, and product availability and formulation must be verified for the relevant date.

Huang and colleagues evaluated eight historical methamphetamine test kits against drugs associated with over-the-counter cold preparations. Ephedrine and pseudoephedrine interfered with several products at the tested concentrations, while other compounds produced product-dependent results. The study demonstrates assay specificity, not a generic rule that taking cold medicine makes every amphetamine or methamphetamine screen positive.

Methamphetamine isomers can answer a different question

Methamphetamine exists in stereoisomeric forms. d-Methamphetamine is the form usually associated with strong central stimulant effects and illicit methamphetamine, while l-methamphetamine has been used in certain over-the-counter nasal inhalers.

Smith and colleagues conducted a controlled study of urine after Vicks VapoInhaler administration. Their work illustrates why a non-chiral confirmation that reports only “methamphetamine” may leave an important source question unresolved. When legitimate l-methamphetamine exposure is plausible, enantiomer-specific or chiral testing can distinguish the forms.

Even then, the conclusion should remain bounded. Isomer analysis may help identify a likely source. It does not by itself establish impairment, exact dose, or exact time of use.

A negative screen also has limits

A negative result does not always mean no exposure occurred. The drug may not be included in the panel, the assay may have limited sensitivity for the relevant compound, the concentration may be below the cutoff, the specimen may have been collected outside the detection window, or dilution may have reduced the measured concentration.

Cutoffs are decision thresholds, not a line between “drug present” and “drug absent” in nature. A specimen just below a cutoff and one with no analyte may both be reported negative, even though they are analytically different.

For a focused analysis of target selection, decision cutoffs, timing, dilution, specimen validity, and device-specific negative interference, read What a Negative Urine Immunoassay Does Not Exclude.

Urine usually does not establish impairment

Urine is an excretion matrix. A urine result can support prior exposure, but it usually does not measure the concentration circulating in blood at the time of an event. Hydration, urine pH, metabolism, dose pattern, collection timing, and the laboratory’s analyte and cutoff rules can all affect the result.

Oyler and colleagues showed in a controlled methamphetamine-administration study that detection timing and duration changed with the reporting cutoffs and with the requirement to detect both methamphetamine and amphetamine. That evidence supports caution, not an exact back-calculation from one urine result to a time of use.

The records needed for a reliable review

A defensible interpretation should identify:

the specimen type and collection time;
chain of custody and specimen-validity information;
the screening manufacturer, assay, drug class, and cutoff;
the raw screening result, not only a summarized label;
the confirmation method, analytes, ion or transition criteria, and cutoffs;
prescription, over-the-counter, supplement, and exposure history;
whether isomer testing was performed when relevant; and
the laboratory’s quality-control, review, and reporting procedures.

A presumptive result can be a legitimate reason to investigate. It should not be presented as chemically specific proof when the record does not contain chemically specific confirmation.

References

Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. Journal of Analytical Toxicology. 2014;38(7):387-396. https://doi.org/10.1093/jat/bku075
Reisfield GM, Goldberger BA, Bertholf RL. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952. https://doi.org/10.4155/bio.09.81
Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy. 2010;67(16):1344-1350. https://doi.org/10.2146/ajhp090477
Smith ML, Nichols DC, Underwood P, et al. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. Journal of Analytical Toxicology. 2014;38(8):524-527. https://doi.org/10.1093/jat/bku077
Oyler JM, Cone EJ, Joseph RE Jr, Moolchan ET, Huestis MA. Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clinical Chemistry. 2002;48(10):1703-1714. https://pubmed.ncbi.nlm.nih.gov/12324487/
Ayala-Lopez N, Colby JM, Hughey JJ. Analysis of electronic health records reveals medication-related interference on point-of-care urine drug screening assays. Journal of Analytical Toxicology. 2022;46(1):99-102. https://doi.org/10.1093/jat/bkaa179
Caricasole V, Spagnolo G, Di Bernardo I, Cirnigliaro G, Piccoli E, Dell’Osso B. Aripiprazole causing false positive urine amphetamine drug screen in an adult patient with bipolar disorder. Comprehensive Psychiatry. 2019;94:152126. https://doi.org/10.1016/j.comppsych.2019.152126
Yee LM, Wu D. False-positive amphetamine toxicology screen results in three pregnant women using labetalol. Obstetrics and Gynecology. 2011;117(2 Pt 2):503-506. https://doi.org/10.1097/AOG.0b013e318206c07c
Bithi N, Jones KE, Straseski JA. Does labetalol trigger false positive drug testing results? Journal of Addiction Medicine. 2023;17(6):e408-e411. https://doi.org/10.1097/ADM.0000000000001183
Reidy L, Walls HC, Steele BW. Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine. Therapeutic Drug Monitoring. 2011;33(3):366-368. https://doi.org/10.1097/FTD.0b013e3182126d08
Vorce SP, Holler JM, Cawrse BM, Magluilo J Jr. Dimethylamylamine: a drug causing positive immunoassay results for amphetamines. Journal of Analytical Toxicology. 2011;35(3):183-187. https://doi.org/10.1093/anatox/35.3.183
Huang BC, Lien MH, Wang PY, Chang BL. Interference by drugs contained in over-the-counter cold syrups on methamphetamine immunoassay test kits used in drug abuse assessment. Journal of Food and Drug Analysis. 1995;3(4):259-268. https://doi.org/10.38212/2224-6614.3007

Educational information only. It is not a case-specific toxicology opinion, a statement of scientific fact, or legal advice.